Online inquiry

IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13912MR)

This product GTTS-WQ13912MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Fibrodysplasia ossificans prograssiva (FOP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13912MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6013MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ6625MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ4437MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ2168MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ2494MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ13032MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ2305MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ5416MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW